Company news
Avalon Globocare Corp. (NASDAQ:ALBT) news
Avalon Globocare Corp. news releases on 6ix. Latest, Jan 17, 2023: Avalon GloboCare Announces Issuance of Key U.S. Patent for Multiple Novel QTY-Code Modified…
Press releases — page 2
Avalon GloboCare Announces Issuance of Key U.S. Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules
January 16, 2023
Avalon GloboCare Appoints Lourdes Felix, CEO of a Premier Addiction Treatment Company, to its Board of Directors
January 10, 2023
Avalon GloboCare Announces the Deployment of Breakthrough Fusion Gene Map Technology
January 2, 2023
Avalon GloboCare Announces $4 Million Private Placement of Preferred Stock with the Company’s Chairman which Converts at a Significant Premium to Market; Proceeds to Support Acquisition of Laboratory Services
December 13, 2022
Avalon GloboCare Continues its U.S. Centric Strategy with a New Proposed Board Composition in Preparation for Acquisition of Laboratory Services MSO, LLC
December 11, 2022
Avalon GloboCare Announces NASDAQ Ticker Symbol Change from “AVCO” to “ALBT”
November 8, 2022
Avalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25 Million
November 7, 2022
Avalon GloboCare Receives Allowance for Joint U.S. Patent
September 28, 2022
Avalon GloboCare Announces Publication Featuring QTY Code Technology in the Official Journal of the American Chemical Society
August 7, 2022
Avalon GloboCare Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer
June 29, 2022
Avalon GloboCare Signs MOU to Form Strategic Partnership with Lu Daopei Hematology Institute to Develop Precision Companion Diagnostics for Cellular Therapy
May 17, 2022
Avalon GloboCare Expands IP Portfolio; Files 16 New Patent Applications
April 26, 2022
Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies
February 13, 2022
Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical Programs
January 3, 2022
Avalon GloboCare’s Chairman Converts Debt into Common Stock at 45% Premium to Market
December 21, 2021
Avalon GloboCare Advances AI-Enhanced Protein Design Technology for Cellular Therapy Development
December 8, 2021
Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular Immunotherapy
October 13, 2021
Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Co-develop Innovative In-Silico Technology, Enabling the Design and Synthesis of Novel Cell Membrane Receptor Targets for Cancer and Immune-Related Diseases
October 6, 2021
Avalon GloboCare Announces its Planned Acquisition Target, SenlangBio, has Initiated First-In-Human Clinical Trial in Recurrent Brain Cancer
June 30, 2021
Avalon GloboCare Announces Execution of Purchase Agreement for Acquisition of SenlangBio in All Stock Transaction
June 13, 2021
Avalon GloboCare Announces Collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center to Advance Clinical Development of Cellular Immunotherapies Using the FLASH-CAR™ Platform
March 28, 2021
Avalon GloboCare Expands Co-Development Program with MIT to Combat Cancer Metastasis
March 21, 2021
Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Expand Partnership and Accelerate Development of S-Layer Based Vaccines and Cellular Therapeutics
December 29, 2020
Avalon GloboCare and Adial Pharmaceuticals Announce Strategic Collaboration for Global Distribution of COVID-19 Point-of-Care Antibody Rapid Test Devices
October 21, 2020
Avalon GloboCare Provides Clinical Updates on Its CAR-T Immuno-Oncology and Allogeneic Mesenchymal Stromal Cell (MSC) Therapy Programs Following Successful Completion of Phase I AVA-001 Clinical Trial
September 30, 2020
Avalon GloboCare Announces Mesenchymal Stromal Cell Therapeutic Platform for COVID-19 and Acute Graft Versus Host Disease (aGVHD)
September 2, 2020
Avalon GloboCare Announces Commercialization and Distribution Agreement with Cellex for COVID-19 Antibody Rapid Test Kit
August 18, 2020
Avalon GloboCare Expands AVA-Trap™ Program to Treat COVID-19 and CAR-T Related Cytokine Storms
August 11, 2020
Avalon GloboCare Provides Updates on its Lead Scientific and Clinical Programs in CAR T-Cell Therapy and COVID-19
July 12, 2020
Avalon GloboCare Announces Successful Completion of Phase I Clinical Study of CAR T-Cell Therapy Candidate AVA-001
June 28, 2020
Avalon GloboCare Achieves Milestones in Advancing Novel Intranasal and Oral COVID-19 Vaccine Candidate
June 24, 2020
Avalon GloboCare Announces Three-Way Material Transfer Agreement with Weill Cornell Medicine and Arbele Limited for Development of Next Generation Cellular Immunotherapy FLASH-CAR™ Technology
June 10, 2020
Avalon GloboCare Announces Diagnostic Platform for Point-of-Care Rapid Detection of COVID-19 (SARS-CoV-2) and Its Clinically Relevant Mutation Strains
June 7, 2020
Avalon GloboCare Advances Next Generation Cellular Immunotherapy with FLASH-CAR™ Technology for Blood Cancers
May 7, 2020
Avalon GloboCare Achieves Major Milestones Advancing Immunotherapeutic Program towards Combatting Cytokine Storm Associated with COVID-19 Lung Damage and Mortality
April 19, 2020
Avalon GloboCare Enters Agreement to Repurchase 100% of Outstanding Warrants
October 20, 2019
Avalon GloboCare Announces Initiation of First-in-Human Clinical Trial of its CAR-T Candidate, AVA-001, for Treatment of B-Cell Malignancies
September 18, 2019
Avalon GloboCare Announces Completion of Clinical-Grade Exosome Bio-Production Standardization with Launch of "ACTEX" Product Commercialization
June 9, 2019
Avalon GloboCare Appoints Finance Veteran Yue ''Charles'' Li to the Board of Directors
April 7, 2019